SRRK - Rasio rega marang prakiraan pendapatan Scholar Rock Holding Corporation

Scholar Rock enjoys high credibility for its innovations in muscle atrophy therapy. The forward price-to-sales valuation reflects the current market value, where the metric stands at 9272.00. Business prospects depend on competing with industry behemoths in the field of gene therapy, while financial stability relies exclusively on the success of clinical trials and the inflow of investments.

Scholar Rock, Inc. - Prakiraan rega marang pendapatan SRRK (periode 04.07.2022 - 15.11.2026)

Rincian analitis perusahaan Scholar Rock

- rega pasar lan target rega analis:

Bagan rega Scholar Rock Corp|SRRK - Bagan rega target

- statistik kapitalisasi pasar:

Nilai pasar Scholar Rock Inc.|SRRK - Total Nilai Perusahaan

- indikator nilai buku ekuitas:

Nilai Buku saben Saham Scholar Rock|SRRK - Nilai Buku Bisnis|Rasio Kapitalisasi marang Aset Bersih scholarrock.com|SRRK - Aset Perusahaan

- data utang lan likuiditas:

Utang marang Ekuitas Scholar Rock|SRRK - Rasio tanggungan utang jangka dawa marang modal|Utang jangka cendhak marang modal Scholar Rock, Inc.|SRRK - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Scholar Rock, Inc.|SRRK - Silihan lan utang jangka dawa perusahaan|Utang jangka cendhak perusahaan Scholar Rock|Likuiditas cepet scholarrock.com

- rincian asil keuangan lan kelipatan valuasi:

SRRK - Bathi resik perusahaan|Proyeksi bathi mangsa ngarep Scholar Rock|SRRK - Pangali P/E|Rega marang bathi mangsa ngarep Scholar Rock|SRRK - Koefisien bali modal nimbang wutah|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Scholar Rock, Inc.|SRRK - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Scholar Rock|SRRK - Bathi saben saham sajroning taun lumaku|Wutah bathi saben saham taun-ka-taun sajrone rolas wulan pungkasan scholarrock.com|SRRK - Kacepetan wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Scholar Rock

- data pendapatan lan penerimaan dodolan:

SRRK - Dodolan perusahaan|Prakiraan pendapatan perusahaan Scholar Rock, Inc.|SRRK - Multiplikator P/S|Rasio rega marang prakiraan pendapatan Scholar Rock Corp

Analisis kabeh metrik perusahaan:Scholar Rock Corp SRRK

For the biotech sector, where Scholar Rock (SRRK) depends on clinical trial outcomes, the expected P/S multiple allows for a comparison of current market value against projected revenue from future drugs. This calculation eliminates time lags between reports, helping investors determine the extent of overpayment for potential earnings and assess the asset's resilience amid regulatory risks.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Jazz Pharma JAZZ|Cytokinetics Corp - Rasio rega marang prakiraan pendapatan|PTCT - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Centessa Pharmaceuticals|DYN (Dyne Corp) - Multiplikator forward rega marang pendapatan|Prakiraan rega marang pendapatan Edgewise Pharma EWTX|Multiplikator forward rega marang pendapatan RAPP|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Alumis Corp ALMS|Multiplikator forward rega marang pendapatan ZVRA (Kempharm)|Multiplikator forward rega marang pendapatan contineum-tx.com CTNM|Multiplikator Forward P/S LRMR (larimartx.com)|Multiplikator Forward P/S Capricor Therapeutics CAPR|TRDA: Multiplikator forward rega marang pendapatan|PTHS - Multiplikator Forward P/S|MNOV: Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan SER|BTAI (BioXcel Therapeutics Inc) - Multiplikator Forward P/S|ProMIS Neurosciences, Inc. (PMN) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S APUS|Rasio rega marang prakiraan pendapatan AEON (AEON Biopharma, Inc.)|Multiplikator Forward P/S NLSP (NLS Pharmaceutics Ltd.)|Rasio kapitalisasi marang dodolan sing dikarepake Bionomics Ltd (BNOX)|HUGE - Rasio rega marang prakiraan pendapatan|Rega forward marang dodolan RETA (Reata Pharmaceuticals, Inc.)